The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and preliminary efficacy of rogaratinib in combination with atezolizumab in a phase Ib/II study (FORT-2) of first-line treatment in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexpression.
 
Jonathan E. Rosenberg
Stock and Other Ownership Interests - Illumina
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Clinical Care Options; ClinicalMind; Intellisphere; Medscape; Peerview; Research To Practice; UpToDate; Vindico
Consulting or Advisory Role - Adicet Bio; Agensys; Astellas Pharma; AstraZeneca/MedImmune; Bayer; BioClin Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; EMD Serono; Fortress Biotech; GlaxoSmithKline; Inovio Pharmaceuticals; Janssen Oncology; Lilly; Merck; Pharmacyclics; QED Therapeutics; Roche/Genentech; Seagen; Sensei Biotherapeutics; western oncolytics
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech/Roche (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Mirati Therapeutics (Inst); Novartis (Inst); QED Therapeutics (Inst); Seagen (Inst); Viralytics (Inst)
Patents, Royalties, Other Intellectual Property - Predictor of platinum sensitivity (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech/Roche
 
Pablo Gajate
Consulting or Advisory Role - Ipsen
Speakers' Bureau - IPSEN; Novartis; Pfizer
Travel, Accommodations, Expenses - Ipsen; Pfizer
 
Rafael Morales-Barrera
Consulting or Advisory Role - AstraZeneca; MSD; Sanofi
Speakers' Bureau - Asofarma; MSD Oncology
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Clovis Oncology; Johnson & Johnson; Lilly; MSD; Roche/Genentech; Sanofi
 
Jae-Lyun Lee
Honoraria - Amgen; Astellas Pharma; Bristol-Myers Squibb; Pfizer
Consulting or Advisory Role - Alteogen; Bristol-Myers Squibb; Pfizer; Sanofi/Aventis
Research Funding - AstraZeneca/MedImmune (Inst); Bayer Schering Pharma (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Andrea Necchi
Employment - Bayer (I)
Stock and Other Ownership Interests - Bayer (I)
Honoraria - AstraZeneca; Bristol-Myers Squibb; Foundation Medicine; Janssen; Merck; Roche
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Ferring; GlaxoSmithKline; Incyte; Janssen; Merck Sharp & Dohme; Rainier Therapeutics; Roche; Seattle Genetics/Astellas
Research Funding - AstraZeneca (Inst); Ipsen; Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Merck Sharp & Dohme; Rainier Therapeutics; Roche
Other Relationship - Bayer (I)
 
Nicolas Penel
Research Funding - Bayer (Inst); Bayer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Astellas Pharma; Janssen-Cilag
Other Relationship - PharmaMar
 
Vittorina Zagonel
Consulting or Advisory Role - Bristol-Myers Squibb; Merck
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Lilly; Roche; SERVIER
Travel, Accommodations, Expenses - Bayer; Roche; SERVIER
 
Mitchell Robert Sierecki
Employment - Bayer
 
Ana-Maria Piciu
Employment - Chrestos
Consulting or Advisory Role - Chrestos
Travel, Accommodations, Expenses - Chrestos
 
Peter Ellinghaus
Employment - Bayer
Stock and Other Ownership Interests - Bayer
Patents, Royalties, Other Intellectual Property - 20180333418
 
Randy F. Sweis
Honoraria - Bristol-Myers Squibb; Exelixis; Medscape
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Eisai; Exelixis; Janssen Oncology; Mirati Therapeutics; Puma Biotechnology
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Eisai (Inst); EpiVax Oncology (Inst); Genentech (Inst); Immunocore (Inst); Merck (Inst); Merck (Inst); Mirati Therapeutics (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb; Eisai; Exelixis